# US 2020/0392497 A1 · Methods and compositions for detecting and promoting cardiolipin remodeling and cardiomyocyte maturation and related methods of treating mitochondrial dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392497 A1
- Document ID: US20200392497A1
- Status: Published application
- Kind: A1
- Application number: 16/770,767
- Filed: 2018-12-07
- Published: 2020-12-17
- Earliest claimed: 2017-12-08
- Assignees: University of Washington
- Applicants: University of Washington
- Inventors: Jason Wayne Miklas; Hannele Ruohola-Baker; Yuliang Wang
- Web page: https://patentgrep.com/patent/US20200392497A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- G01N 33/5061: {Muscle cells}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2330/50: Biochemical production, i.e. in a transformed host cell
- C12N 2501/65: MicroRNA
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Embodiments of the disclosure relate to methods and compositions for inducing maturation of cardiomyocytes. In some embodiments, the cardiomyocytes are derived from stem cells, in vitro. In some embodiments, the compositions and methods induce maturation by inducing overexpression of a Let7i microRNA (miRNA), overexpression of miR-452, reduced expression of miR-122, and/or reduced expression of miR-200a in the cardiomyocyte. In other embodiments, the disclosure relates to methods for treating conditions characterized by mitochondrial dysfunction, such as fatty acid oxidations disorders. In other embodiments, the disclosure relates to methods of screening for compounds that affect heart muscle function. In yet other embodiments, the disclosure relates to methods for detecting or monitoring mitochondrial dysfunction in a cell by detecting or monitoring the cardiolipin profile of the cell.

## Claims

### Claim 1

A method for inducing maturation of cardiomyocyte, comprising inducing in an immature cardiomyocyte two or more of the following: overexpression of a Let7i microRNA (miRNA), overexpression of miR-452, reduced expression of miR-122, and reduced expression of miR-200a.

### Claim 2 (depends on 1)

The method of claim 1, comprising inducing in an immature cardiomyocyte three or more of the following: overexpression of a Let7i miRNA, overexpression of miR-452, reduced expression of miR-122, and reduced expression of miR-200a.

### Claim 3 (depends on 2)

The method of claim 2, comprising inducing in an immature cardiomyocyte overexpression of a Let7i miRNA, overexpression of miR-452, reduced expression of miR-122, and reduced expression of miR-200a.

### Claim 4 (depends on 1, 2, 3)

The method of one of claims 1-3, wherein inducing overexpression comprises contacting the immature cardiomyocyte with a vector comprising a nucleic acid encoding the miRNA to be overexpressed.

### Claim 5 (depends on 4)

The method of claim 4, wherein the vector is configured to promote transient expression of the nucleic acid encoding the miRNA to be overexpressed.

### Claim 6 (depends on 4)

The method of claim 4, wherein the vector is a viral vector configured to integrate the nucleic acid encoding the miRNA to be overexpressed into the genome of the immature cardiomyocyte.

### Claim 7 (depends on 6)

The method of claim 6, wherein the viral vector is a lentiviral vector or an adeno-associated viral vector.

### Claim 8 (depends on 1, 2, 3)

The method of one of claims 1-3, wherein inducing reduced expression of an miRNA comprises contacting the immature cardiomyocyte with a nucleic acid fragment that hybridizes to the miRNA targeted for reduced expression, or with a vector comprising a nucleic acid encoding a transcript that hybridizes to the miRNA targeted for reduced expression.

### Claim 9 (depends on 1)

The method of claim 1, wherein inducing reduced expression comprises implementing a knockout of a gene encoding the miRNA.

### Claim 10 (depends on 1, 2, 3)

The method of one of claims 1-3, wherein inducing reduced expression comprises providing the immature cardiomyocyte with nuclease enzyme and a guide nucleic acid with a sequence to facilitate the specific cleavage of a nucleic acid encoding the miRNA targeted for reduced expression by the nuclease enzyme.

### Claim 11 (depends on 10)

The method of claim 10, wherein providing the providing the immature cardiomyocyte with a nuclease enzyme comprises contacting the immature cardiomyocyte with the nuclease enzyme or with a vector encoding the nuclease enzyme, wherein the vector is configured to promote expression of the enzyme in the cardiomyocyte.

### Claim 12 (depends on 10)

The method of claim 10, wherein providing the providing the immature cardiomyocyte with a guide nucleic acid comprises contacting the immature cardiomyocyte with the guide nucleic acid or with a vector encoding the guide nucleic acid, wherein the vector is configured to promote expression of the guide nucleic acid in the cardiomyocyte.

### Claim 13 (depends on 10)

The method of claim 10, wherein the nuclease enzyme is an endonuclease, such as Cas9 or TALENS.

### Claim 14 (depends on 8, 11)

The method of one of claim 8, 11, or 12 wherein the vector is a viral vector.

### Claim 15 (depends on 14)

The method of claim 14, where the viral vector is a lentiviral vector or an adeno-associated viral vector.

### Claim 16 (depends on 1)

The method of claim 1, wherein the immature cardiomyocyte is derived from a stem cell.

### Claim 17 (depends on 14)

The method of claim 14, wherein the immature cardiomyocyte is derived from a stem cell in vitro.

### Claim 18 (depends on 16, 17)

The method of claim 16 or claim 17, wherein the stem cell is an embryonic stem cell, pluripotent stem cell, or induced pluripotent stem cell.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of one of claims 1-18, further comprising contacting the immature cardiomyocyte with two or more long-chain fatty acids selected from palmitic acid, oleic acid, and linoleic acid.

### Claim 20 (depends on 19)

The method of claim 19, wherein the one or more long chain fatty acids comprise palmitate, oleic acid, and linoleic acid.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of one of claims 1-20, wherein the cardiomyocyte comprises a genetic aberration.

### Claim 22 (depends on 21)

The method of claim 21, wherein the genetic aberration is associated with a metabolic or pathological disease state in the heart.

### Claim 23 (depends on 22)

The method of claim 22, wherein the genetic aberration is associated with a fatty acid oxidation (FAO) disorder.

### Claim 24 (depends on 22)

The method of claim 22, wherein the cardiomyocyte comprises a mutation in a gene encoding one of the following: HADHA, FATP1, FACS1, OCTN2, L-CPTI, M-CPT I, CAT, CPT II, VLCAD, LCAD, MCAD, SCAD, LCHAD, SHYD, M/SCHAD, SKAT, MKAT, HS, HL, ETF, and ETF QO.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A cardiomyocyte produced by any method recited in one of claims 1-24.

### Claim 26 (depends on 25)

The cardiomyocyte of claim 25, wherein the cardiomyocyte comprises a genetic aberration.

### Claim 27 (depends on 26)

The cardiomyocyte of claim 26, wherein the genetic aberration is associated with a fatty acid oxidation (FAO) disorder.

### Claim 28 (depends on 27)

The cardiomyocyte of claim 27, wherein the genetic aberration is a mutation in the gene encoding HADHA.

### Claim 29 (depends on 25)

A method of treating a subject with a condition treatable by administration of cardiomyocytes with a mature cardiolipin profile, comprising administering to the subject an effective amount of cardiomyocytes as recited in claim 25.

### Claim 30 (depends on 29)

The method of claim 29, wherein the subject has compromised cardiac tissue or cells.

### Claim 31 (depends on 29)

The method of claim 29, wherein the subject has diabetes, congenital heart disease, ischemia, myopathy, mitochondrial disease, and/or has suffered from infarction.

### Claim 32 (depends on 29)

The method of claim 29, wherein the mitochondrial disease is a fatty acid oxidation (FAO) disorder.

### Claim 33 (depends on 29)

The method of claim 29, wherein the subject has a mutation in the gene encoding HADHA.

### Claim 34 (depends on 29)

The method of claim 29, wherein the subject experiences arrhythmia.

### Claim 35 (depends on 29)

The method of claim 29, wherein the subject is at an elevated risk of sudden infant death syndrome (SIDS).

### Claim 36 (depends on 25, 26, 27, 28)

A method of screening a compound for modulation of heart function, comprising:
contacting one or more cardiomyocytes as recited in one of claims 25-28 with a candidate agent; and
measuring a cardiac functional parameter in the one or more cardiomyocytes;
wherein a change in the cardiac functional parameter indicates the candidate agent modulates heart function.

### Claim 37 (depends on 36)

The method of claim 36, wherein the mature cardiomyocyte comprises a genetic aberration.

### Claim 38 (depends on 37)

The method of claim 37, wherein the genetic aberration is associated with a fatty acid oxidation (FAO) disorder.

### Claim 39 (depends on 38)

The method of claim 38, wherein the genetic aberration is a mutation in the gene encoding HADHA.

### Claim 40 (depends on 36)

The method of claim 36, wherein the cardiac functional parameter comprises lipid profile, cardiolipin profile, metabolic profile, oxygen consumption rate, mitochondrial proton gradient, force of contraction, calcium transport, conduction velocity, glucose stress, and cell death.

### Claim 41

A method of treating a mitochondrial fatty acid oxidation (FAO) disorder in a subject, the method comprising administering an effective amount of a composition stabilizing a cardiolipin profile or promoting mature cardiolipin remodeling in mitochondria of the subject.

### Claim 42 (depends on 41)

The method of claim 41, wherein the FAO disorder is associated with diabetes, heart failure, neurodegeneration, advanced age, congenital heart disease, ischemia, myopathy, and/or instance of infarction.

### Claim 43 (depends on 41)

The method of claim 41, wherein the FAO disorder is a fatty acid (FA) β-oxidation disorder.

### Claim 44 (depends on 41)

The method of claim 41, wherein a phenotype of the mitochondrial dysfunction is associated with increased risk of sudden infant death syndrome.

### Claim 45 (depends on 41)

The method of claim 41, wherein stabilizing a cardiolipin profile comprises prevention of oxidation of cardiolipin.

### Claim 46 (depends on 41, 42, 43, 44, 45)

The method of claims 41-45, wherein the composition is or comprises elamipretide.

### Claim 47

A method of detecting the pathological state of a cultured cardiomyocyte comprising,
determining the cardiolipin profile in the cardiomyocyte, wherein a relative increase of cardiolipins with acyl chains with more than 18 carbons indicates and a relative decrease in cardiolipins with acyl chains with less than 18 carbons indicates a reduced pathological state of the cardiomyocyte.

### Claim 48 (depends on 47)

The method of claim 47, wherein the increase or decrease of cardiolipins is relative to a wild-type immature cardiomyocyte.

### Claim 49 (depends on 47)

The method of claim 47, wherein the cultured cardiomyocyte is derived from a stem cell in vitro.

### Claim 50 (depends on 49)

The method of claim 49, wherein the stem cell is an embryonic stem cell, pluripotent stem cell, or induced pluripotent stem cell.

### Claim 51 (depends on 47)

The method of claim 47, wherein the pathological state is associated with a mitochondrial dysfunction.

### Claim 52 (depends on 51)

The method of claim 51, wherein the mitochondrial dysfunction is mitchondrial tri-functional protein deficiency.

### Claim 53 (depends on 47)

The method of claim 47, further comprising contacting the cultured cardiomyocyte with a candidate agent for reducing the pathological state of the cultured cardiomyocyte.

### Claim 54 (depends on 53)

The method of claim 53, comprising determining the cardiolipin profile in the cultured cardiomyocyte a plurality of times before, during, and/or after the step of contacting the cultured cardiomyocyte with a candidate agent to ascertain the effect of the candidate agent on the pathological state of the cultured cardiomyocyte.

### Claim 55

A composition to induce maturation of a cultured cardiomyocyte, comprising two or more of the following: a nucleic acid construct encoding a Let7i microRNA, a nucleic acid construct encoding miR-452, a nucleic acid construct that is or encodes an oligomer that hybridizes to a portion of a sequence encoding miR-122, and a nucleic acid construct that is or encodes an oligomer that hybridizes to a portion of a sequence encoding miR-200a.

### Claim 56 (depends on 55)

The composition of claim 55, comprising three or more of the following: a nucleic acid construct encoding a Let7i microRNA, a nucleic acid construct encoding miR-452, a nucleic acid construct that is or encodes an oligomer that hybridizes to a portion of a sequence encoding miR-122, and a nucleic acid construct that is or encodes an oligomer that hybridizes to a portion of a sequence encoding miR-200a.

### Claim 57 (depends on 55)

The composition of claim 55, comprising a nucleic acid construct encoding a Let7i microRNA, a nucleic acid construct encoding miR-452, a nucleic acid construct that is or encodes an oligomer that hybridizes to a portion of a sequence encoding miR-122, and a nucleic acid construct that is or encodes an oligomer that hybridizes to a portion of a sequence encoding miR-200a.

### Claim 58 (depends on 55, 56, 57)

The composition of one of claims 55-57, wherein the nucleic acid constructs that encode a microRNA and/or encode an oligomer are each operatively linked to one or more promoter sequences.

### Claim 59 (depends on 55, 56, 57)

The composition of one of claims 55-57, wherein one or more of the constructs are incorporated into one or more vectors configured for delivery to a cell.

### Claim 60 (depends on 59)

The composition of claim 59, wherein the one or more vectors are viral vectors.

### Claim 61 (depends on 60)

The composition of claim 60, wherein at least one viral vector is a lentiviral vector or AAV vector.

### Claim 62 (depends on 55, 56, 57, 58, 59, 60, 61)

The composition of one of claims 55-61, wherein the oligomer that hybridizes to a portion of a sequence encoding miR-122 and the oligomer that hybridizes to a portion of a sequence encoding miR-200a are guide RNA molecules that are configured to induce a gene editing enzyme to cleave miR-122 and miR-200a, respectively.

### Claim 63 (depends on 62)

The composition of claim 62, wherein the gene editing enzyme is a nuclease.

### Claim 64 (depends on 55, 56, 57, 58, 59, 60, 61, 62, 63)

The composition of one of claims 55-63, further comprising a nuclease.

### Claim 65 (depends on 63, 64)

The composition of claim 63 or claim 64, wherein the nuclease is Cas9.

### Claim 66 (depends on 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The composition of one of claims 55-65, further comprising one or more long-chain fatty acids.

### Claim 67 (depends on 66)

The composition of claim 66, wherein the one or more long-chain fatty acids comprise two or more of palmitate, oleic acid, and linoleic acid.

### Claim 68 (depends on 67)

The composition of claim 67, wherein the one or more long-chain fatty acids comprise palmitate, oleic acid, and linoleic acid.
